HilleVax, Inc. (HLVX)
Largest Insider Buys in Sector
HLVX Stock Price History Chart
HLVX Stock Performance
About HilleVax, Inc.
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Insider Activity of HilleVax, Inc.
Over the last 12 months, insiders at HilleVax, Inc. have bought $149,550 and sold $1.95M worth of HilleVax, Inc. stock.
On average, over the past 5 years, insiders at HilleVax, Inc. have bought $15.07M and sold $493.96M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Frazier Life Sciences X, L.P. (10 percent owner) — $128,325. McLoughlin Sean (Chief Operating Officer) — $21,225.
The last purchase of 8,850 shares for transaction amount of $128,325 was made by Frazier Life Sciences X, L.P. (10 percent owner) on 2024‑04‑04.
List of Insider Buy and Sell Transactions, HilleVax, Inc.
| 2024-05-22 | Sale | director | 6,000 0.0126% | $14.73 | $88,372 | -86.71% | ||
| 2024-05-21 | Sale | director | 6,000 0.0118% | $14.21 | $85,230 | -87.01% | ||
| 2024-05-20 | Sale | director | 6,000 0.0129% | $15.45 | $92,689 | -86.99% | ||
| 2024-05-03 | Sale | director | 723 0.0015% | $14.15 | $10,233 | -86.04% | ||
| 2024-05-02 | Sale | director | 6,000 0.0121% | $14.01 | $84,081 | -86.41% | ||
| 2024-05-01 | Sale | director | 175 0.0004% | $14.03 | $2,456 | -85.92% | ||
| 2024-04-05 | Sale | director | 6,000 0.012% | $14.44 | $86,640 | -86.71% | ||
| 2024-04-04 | Sale | director | 6,000 0.0122% | $14.71 | $88,245 | -86.66% | ||
| 2024-04-04 | 10 percent owner | 8,850 0.0178% | $14.50 | $128,325 | -86.66% | |||
| 2024-04-03 | Sale | director | 6,000 0.0122% | $14.93 | $89,582 | -86.91% | ||
| 2024-03-28 | Chief Operating Officer | 1,250 0.0026% | $16.98 | $21,225 | -88.33% | |||
| 2024-03-20 | Sale | director | 6,000 – | $164,221.00 | $985.33M | -87.83% | ||
| 2024-03-19 | Sale | director | 6,000 0.0126% | $17.42 | $104,492 | -88.75% | ||
| 2024-03-18 | Sale | director | 6,000 0.0129% | $17.66 | $105,937 | -88.70% | ||
| 2024-03-08 | Sale | director | 6,000 0.0128% | $18.66 | $111,959 | -89.31% | ||
| 2024-03-07 | Sale | director | 6,000 0.0124% | $18.37 | $110,213 | -89.43% | ||
| 2024-03-06 | Sale | director | 6,000 0.0128% | $18.95 | $113,701 | -89.56% | ||
| 2024-02-22 | Sale | director | 6,000 0.0127% | $15.05 | $90,312 | -86.64% | ||
| 2024-02-21 | Sale | director | 6,000 0.0126% | $14.92 | $89,495 | -86.42% | ||
| 2024-02-20 | Sale | director | 6,000 0.0127% | $14.88 | $89,272 | -86.23% |
Insider Historical Profitability
| Frazier Life Sciences X, L.P. | 10 percent owner | 8544187 17.1549% | $1.88 | 1 | 0 | |
| McLoughlin Sean | Chief Operating Officer | 1250 0.0025% | $1.88 | 1 | 0 | |
| Heron Patrick J | 8535337 17.1371% | $1.88 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Frazier Life Sciences Management L P | $162.67M | 19.67 | 9.78M | 0% | +$0 | 7.35 | |
| Deerfield Management | $66.59M | 8.05 | 4M | 0% | +$0 | 0.16 | |
| T Rowe Price Investment Management Inc | $50.92M | 6.16 | 3.06M | +110.6% | +$26.74M | 0.03 | |
| Deep Track Capital Lp | $42.78M | 5.17 | 2.57M | -11.29% | -$5.45M | 0.2 | |
| Vr Adviser Llc | $34.51M | 4.17 | 2.08M | 0% | +$0 | 1.68 |